Tesco's Leahy cashes in before checking out
Tesco's departing chief executive Sir Terry Leahy has pocketed more than £3.3m from a sale of shares in the UK's number one supermarket.
Tesco's departing chief executive Sir Terry Leahy has pocketed more than £3.3m from a sale of shares in the UK's number one supermarket.
He sold 764,576 shares at 432.3p a go. Tesco did not disclose how many shares he still has, if any.
Sir Terry's retirement from the company was announced in June. He is stepping down in March after 14 years as chief executive. He will be replaced by Phil Clarke, currently responsible for international operations.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
'When I became CEO I had a plan to build Tesco around its customers, to make it number one in the UK and to find new long term growth in non-food, in services and in international expansion,' he said, as the company announced his departure.
'It has taken 14 years but that strategy has become a firm reality now and so I feel my work is almost complete,' he added.
Tesco overtook Sainsbury's as the UK's top supermarket in 1995. Earlier this month it posted a 12% rise in first half profits despite sluggish underlying sales in the UK.
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
-
What the Employment Rights Bill means for your job
New workplace reforms are set to give employees new rights to benefits and flexible working
By Marc Shoffman Published
-
GSK share price surges after $2.2bn Zantac drug settlement
GSK has settled lawsuits in the US that alleged the drugmaker’s now-discontinued heartburn drug Zantac triggered cancer
By Chris Newlands Published